Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells
FOSTER CITY, Calif. & SANTA MONICA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), Kite, a Gilead Company, and oNKo-innate announced the companies have entered into a three-year cancer immunotherapy research collaboration to support discovery and development of next-generation drug and engineered cell therapies focused on natural killer (NK) cells. Current cancer immunotherapy approaches primarily focus on T cell mediated anti-tumor immunity, including che
